Propofol Injectable Emulsion, USP is supplied as follows:
Unit of Sale | Concentration |
NDC 0069-0209-05 Carton of 5 Single-Patient Use Vials | 200 mg/20 mL (10 mg/mL) |
NDC 0069-0209-10 Carton of 10 Single-Patient Use Vials | 200 mg/20 mL (10 mg/mL) |
NDC 0069-0209-25 Carton of 25 Single-Patient Use Vials | 200 mg/20 mL (10 mg/mL) |
NDC 0069-0234-01 Carton of 1 Single-Patient Use Vials | 500 mg/50 mL (10 mg/mL) |
NDC 0069-0234-05 Carton of 5 Single-Patient Use Vials | 500 mg/50 mL (10 mg/mL) |
NDC 0069-0234-20 Carton of 20 Single-Patient Use Vials | 500 mg/50 mL (10 mg/mL) |
NDC 0069-0248-01 Carton of 1 Single-Patient Use Vials | 1,000 mg/100 mL (10 mg/mL) |
NDC 0069-0248-10 Carton of 10 Single-Patient Use Vials | 1,000 mg/100 mL (10 mg/mL) |
Propofol undergoes oxidative degradation, in the presence of oxygen, and is therefore packaged under nitrogen to eliminate this degradation path.
Store between 4°C to 25°C (40°F to 77°F). Do not freeze. Shake well before use.
Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing.
Propofol Injectable Emulsion, USP is supplied as follows:
Unit of Sale | Concentration |
NDC 0069-0209-05 Carton of 5 Single-Patient Use Vials | 200 mg/20 mL (10 mg/mL) |
NDC 0069-0209-10 Carton of 10 Single-Patient Use Vials | 200 mg/20 mL (10 mg/mL) |
NDC 0069-0209-25 Carton of 25 Single-Patient Use Vials | 200 mg/20 mL (10 mg/mL) |
NDC 0069-0234-01 Carton of 1 Single-Patient Use Vials | 500 mg/50 mL (10 mg/mL) |
NDC 0069-0234-05 Carton of 5 Single-Patient Use Vials | 500 mg/50 mL (10 mg/mL) |
NDC 0069-0234-20 Carton of 20 Single-Patient Use Vials | 500 mg/50 mL (10 mg/mL) |
NDC 0069-0248-01 Carton of 1 Single-Patient Use Vials | 1,000 mg/100 mL (10 mg/mL) |
NDC 0069-0248-10 Carton of 10 Single-Patient Use Vials | 1,000 mg/100 mL (10 mg/mL) |
Propofol undergoes oxidative degradation, in the presence of oxygen, and is therefore packaged under nitrogen to eliminate this degradation path.
Store between 4°C to 25°C (40°F to 77°F). Do not freeze. Shake well before use.
Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing.
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.